TNF and influenza: De Bruyn et al. [26] demonstrated that serologic protection to influenza vaccine is achieved in approximately 45–80% of IBD patients on maintenance anti-TNF therapy, and that this was not affected by alterations to vaccination scheduling around this therapy.